Amneal (AMRX) | Stock Overview & Key Data
Amneal Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $24.48 on August 20, 2018
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Amneal AMRX | 3.68B Mid-cap | 0.49% | 8.41% | 18.03% | 2.36% | 6.31% | 16.97% | 168.69% | 73.05% |
| Zoetis ZTS | 70.27B Large-cap | 2.18% | -6.53% | -0.27% | -2.53% | -2.11% | -9.02% | -10.56% | 16.11% |
| Haleon Plc - ADR HLN | 47.20B Large-cap | -2.90% | -7.63% | 7.49% | 5.90% | 6.46% | 14.04% | 36.98% | 36.98% |
| Regencell Bioscience RGC | 18.54B Large-cap | 32.26% | -96.98% | -31.65% | 277.15% | 300.62% | 426.57% | -50.59% | 75.52% |
| Elanco Animal Health ELAN | 6.63B Mid-cap | 2.22% | 5.96% | 77.07% | 27.71% | 22.41% | 4.78% | -27.94% | -39.18% |
| Lantheus Holdings LNTH | 5.60B Mid-cap | 3.76% | -0.97% | -11.78% | -12.33% | -7.20% | -35.84% | 12.09% | 402.79% |
Amneal Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Amneal would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is AMRX's 52-week high and low?
In the last 52 weeks, Amneal reached a high of $9.48 (on November 12, 2024) and a low of $6.50 (on August 5, 2024).
What is the market cap and P/E ratio for AMRX?
Curious about Amneal's size and valuation? Its market capitalization stands at 3.68B. When it comes to valuation, the P/E ratio (trailing twelve months) is 89.83, and the forward P/E (looking ahead) is N/A.
Does AMRX pay dividends? If so, what's the yield?
As for dividends, Amneal isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Amneal's main competitors or similar companies to consider before investing?
When looking at Amneal, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Zoetis ZTS | 70.27B | Healthcare | Drug Manufacturers - Specialty & Generic | -9.02% | -10.56% |
| Haleon Plc - ADR HLN | 47.20B | Healthcare | Drug Manufacturers - Specialty & Generic | 14.04% | 36.98% |
| Regencell Bioscience RGC | 18.54B | Healthcare | Drug Manufacturers - Specialty & Generic | 426.57% | -50.59% |
| Elanco Animal Health ELAN | 6.63B | Healthcare | Drug Manufacturers - Specialty & Generic | 4.78% | -27.94% |
| Lantheus Holdings LNTH | 5.60B | Healthcare | Drug Manufacturers - Specialty & Generic | -35.84% | 12.09% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Amneal Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
To get a sense of Amneal's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is N/A, the Debt to Equity ratio from the most recent quarter is N/A, and its Gross Profit Margin stands at N/A.
What is the recent revenue and earnings growth for AMRX?
Looking at Amneal's growth, its revenue over the trailing twelve months (TTM) was N/A. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
How much of AMRX stock is held by insiders and institutions?
Wondering who owns Amneal stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.